Guardant Health Inc. stocks have been trading up by 17.09 percent after upbeat news on its cancer diagnostics pipeline.
Click Here for a Millionaire's POV on Trading GH
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways For GH Traders
- Q1 sales jumped 48% to about $302M, powered by 47% oncology testing growth and Shield screening revenue exploding from $5.7M to $41.6M.
- Management lifted its FY26 revenue outlook to $1.30B–$1.32B, keeping strong margins but still expecting negative free cash flow.
- Major banks, including Baird, JPMorgan, Barclays and Piper Sandler, raised price targets on GH and reiterated bullish ratings.
- CFRA kept a Buy on GH but trimmed its 12‑month target to $112, pointing to ongoing losses and slightly softer margin guidance.
- RSU grants to 267 hires and a 50,000‑share sale by Co‑CEO AmirAli Talasaz highlight both growth hiring and normal insider activity.
Live Update At 16:02:48 EDT: On Wednesday, May 20, 2026 Guardant Health Inc. stock [NASDAQ: GH] is trending up by 17.09%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
Guardant Health, trading as GH, is acting like a classic high‑growth story that the market is finally rewarding. Over the last few weeks, GH has run from $84.00–$88.00 into the mid‑$110s, with the latest close near $114.97 after a strong intraday push. That’s a powerful breakout, not a slow grind.
On the daily chart, GH has stacked higher lows from 2026/04/29 onward, turning prior resistance around the low‑$90s into support. The big range day on 2026/05/20–2026/05/21, when GH surged from roughly $95 to above $114, tells traders that fresh buyers are chasing the earnings story, not fading it.
Intraday, the 5‑minute tape shows steady higher highs through the afternoon, with GH holding above $110 and then stair‑stepping into the close. That type of trend day often attracts momentum traders looking for continuation.
More Breaking News
- MRVL Stock Climbs As Wall Street Supercharges AI Price Targets
- HIVE Stock Grinds Higher As Traders Eye Breakout
- SLNH Stock Eyed As 2.46M Share Resale Looms
- VIDA Global Pops Onto Wall Street As AI Agent IPO In Focus
Fundamentally, GH is still losing money — Q1 net loss was about $112.1M and margins are negative at the operating and net level. But revenue of roughly $301.7M, asset turnover of 0.6, and a thick 64.5% gross margin show a business scaling fast. With a current ratio of 4.8 and more than $989M in cash, GH has runway to keep funding growth, which is exactly what momentum‑focused traders like to see in a hot biotech name.
Why Traders Are Watching GH Now
Traders are locked on GH because this is the kind of earnings inflection that often drives multi‑month trends. Guardant Health just printed a standout Q1: sales jumped 48% year over year to about $302M, while oncology testing volumes climbed 47%. The headline grabber was Shield, GH’s blood‑based screening test. Shield revenue exploded from $5.7M to $41.6M, more than 600% growth, with volumes up nearly 400%.
When a product like Shield scales that fast, it usually means the market is embracing it, not just trying it. GH backed that up by nudging gross margin to 66%, even with all that volume. For traders, rising revenue plus rising gross margin is what supports premium price‑to‑sales multiples in high‑growth diagnostics.
Management didn’t just celebrate the quarter; they raised the FY26 revenue outlook to $1.30B–$1.32B, above prior guidance and Street consensus. That tells traders the growth is not a one‑off spike. GH still expects negative free cash flow versus 2025, but they’re signaling a path toward better cash burn as they scale.
The Street piled on. Baird boosted its GH target to $129 and kept an Outperform rating. JPMorgan and Piper Sandler both lifted targets to $135 with Overweight ratings, while Barclays raised from $115 to $120 and stayed Overweight. Each bank cited GH’s leadership in next‑generation sequencing and the higher 2026 outlook as support for a premium valuation.
On top of that, Guardant Health announced a nationwide collaboration with Quest Diagnostics. For GH traders, that’s big: Quest brings broad distribution and physician access, which can push Shield adoption far beyond current levels. CFRA did trim its 12‑month GH target to $112 even while reiterating a Buy, reminding traders that losses and slightly lower gross‑margin guidance still matter. But the tone across GH coverage is clearly bullish.
Conclusion
Guardant Health is a textbook high‑growth, high‑volatility story that attracts active traders. GH is posting rapid top‑line growth, with Q1 revenue near $301.7M, Shield up more than 600%, and oncology testing volumes climbing almost 50%. Management raised the FY26 target to $1.30B–$1.32B and locked in a 66% gross margin, while the new Quest Diagnostics collaboration adds another leg to the growth stool.
At the same time, GH remains unprofitable, with an EBIT margin around ‑42% and profit margins still deep in the red. Free cash flow for the latest quarter was about ‑$71.2M. CFRA’s trimmed $112 target and the 50,000‑share sale by Co‑CEO AmirAli Talasaz are good reminders that not everyone is ignoring the risk side, even if he still controls about 2.1M shares. RSU grants to 267 new non‑executive employees also mean ongoing stock‑based dilution as GH hires aggressively.
For traders, the lesson is simple: this is a momentum name with real numbers behind the hype, but it’s still a work‑in‑progress business. As Tim Sykes loves to say, “The market doesn’t reward potential forever — it rewards execution, and punishes anyone who overstays when the trend breaks.” That’s why, as Tim Bohen, lead trainer with StocksToTrade says, “A good trade setup checks all the boxes—volume, trend, catalyst. Don’t trade if you’re missing pieces of the puzzle.”. GH is executing right now; the trend is up. Your job as a trader is to study the chart, track the earnings story, and always, always have an exit plan.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.